Best of ASCO - 2014 Annual Meeting



Attend this session at the
2017 ASCO Annual Meeting!

Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Type: Oral Abstract Session

Time: Saturday June 3, 3:00 PM to 6:00 PM

Location: S100bc

Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.

Non-Hodgkin Lymphoma

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

2017 ASCO Annual Meeting

Abstract No:

J Clin Oncol 35, 2017 (suppl; abstr 7506)

Author(s): Michael Pfreundschuh, Konstantinos Christofyllakis, Bettina Altmann, Marita Ziepert, Mathias Haenel, Andreas Viardot, Andreas Neubauer, Gerhard Held, Lorenz Truemper, Christian Schmidt, Lothar Kanz, Michael J. Hallek, Norbert Schmitz, Tobias Heintges, Christian Koelbel, Guenther Schneider, Christian Ruebe, Dirk Hellwig, Viola Poeschel, Niels Murawski; University Saarland Medical School‎, Homburg Saar, Germany; Saarland University Medical Center, Homburg, Germany; Institute for Medical Informatics, Statistics and Epidemology, Leipzig University, Leipzig, Germany; Klinik für Innere Medizin III, Klinikum Chemnitz, Chemnitz, Germany; Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany; University Clinic Giessen Marburg, Marburg, Germany; Saarland University Medical School, Homburg, Germany; University Medical Center Göttingen, Göttingen, Germany; University Hospital of Munich, Munich, Germany; Medizinische Uniklinik Tuebingen, Tuebingen, Germany; University Hospital Cologne, Cologne, Germany; Asklepios Hospital St. Georg, Hamburg, Germany; Medical Department II, Städtisches Klinikum Neuss Lukaskrankenhaus GmbH, Neuss, Germany; Krankenhaus der Barmherzigen Brueder, Trier, Trier, Germany; Department of Diagnostic and Interventional Radiology, Saarland University Hospital, Homburg, Germany; Universitätsklinikum Regensburg, Regensburg, Germany

Abstract Disclosures


Background: RT to bulky sites improves outcome of elderly DLBCL patients [Lancet Oncol 2008; 9: 105-116; J Clin Oncol 2014; 32:112-1118]. Whether RT can be spared in PET-negative pts. after R-CHOP was prospectively addressed in OPTIMAL >60. Methods: 61 to 80 y-old pts. were randomized in a 2x2 factorial design to 6xCHOP-14 or 6xCHLIP-14 (liposomal instead of conventional vincristine) plus 8 x rituximab 375 mg/m2(R) q 2 wks. or 12xR (days -4,-1,1,4,14,28,42,56,91,126,175, 238). Pts. with bulk (>=7.5 cm) PET-positive after 6 cycles chemotherapy were assigned to RT (39.6 Gy), while PET-negative bulks were observed. Results: 187/505 (37%) had bulky disease and were compared to 117/306 (38%) RICOVER-60 pts. (38%) who had received 6xCHOP-14+8R. OPTIMAL>60 pts. were older (70 vs. 68 years) and had more IPI=3 (33% vs. 29%) and IPI=4,5 (34% vs. 23%) compared to RICOVER-60. PET was performed in 166/187 OPTIMAL>60 bulk pts. (reasons for no PET: early death: 5; excessive toxicity: 3; protocol violation: 1, non-compliance: 4, change of diagnosis: 6, others: 2). 80/166 (48%) bulks remained PET-positive after 6 cycles of chemotherapy and 62/80 (78%) were irradiated (reasons for no RT: progression: 8; medical reasons: 9; negative biopsy: 1), reducing RT from 67/117 (57%) in RICOVER-60 by 42% to 62/187 (33%) in OPTIMAL>60. Despite the unfavorable demographics, outcome of the 187 bulk pts. in OPTIMAL>60 was non-inferior to RICOVER-60, not even in the least intensive of the 4 OPTIMAL>60 treatment arms consisting of 47 pts. who received 6xCHOP-14+8R as in RICOVER-60. 2-year PFS and OS in OPTIMAL>60 was 79% and 88%, respectively, compared to 75% and 78% of the 117 RICOVER-60 pts. In a multivariable analysis adjusting for the IPI risk factors, the hazard ratio of the OPTIMAL>60 compared to the RICOVER-60 bulk pts. was 0.7 (95% CI: 03.; 1.5; p=0.345) for PFS and 0.5 (95% CI: 02.; 1.3; p=0.154) for OS. Conclusions: RT can be spared in bulky disease PET-negative after chemotherapy. This strategy results in a 42% reduction of RT without compromising the outcome of these patients. Supported by Amgen, Roche, Spectrum. Clinical trial information: NCT01478542

Other Abstracts in this Sub-Category:


1. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.

Meeting: 2017 ASCO Annual Meeting Abstract No: 7501 First Author: Mathias J. Rummel
Category: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia - Non-Hodgkin Lymphoma


2. Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).

Meeting: 2017 ASCO Annual Meeting Abstract No: 7502 First Author: David Jacob Andorsky
Category: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia - Non-Hodgkin Lymphoma


3. Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma.

Meeting: 2017 ASCO Annual Meeting Abstract No: 7507 First Author: Michael C. Jin
Category: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia - Non-Hodgkin Lymphoma